Two- and three-dimensional cell structures govern epidermal growth factor survival function in human bladder carcinoma cell lines

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3360-3364

  Dangles, Virginie ^a,b   Féménia, Françoise ^b   Lainé, Véronique ^b   Berthelemy, Madeleine ^b   Le Rhun, Danielle ^b   Poupon, Marie France ^c   Levy, Daniel ^b   Schwartz Cornil, Isabelle ^b  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^c INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GENISTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TYRPHOSTIN;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL CULTURE; CELL STRUCTURE; CELL SURVIVAL; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STARVATION;

APOPTOSIS; CULTURE MEDIA, SERUM-FREE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; EPIDERMAL GROWTH FACTOR; GENISTEIN; HUMANS; ISOFLAVONES; NEOPLASM PROTEINS; NITRILES; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPHEROIDS, CELLULAR; TIME FACTORS; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED; TYRPHOSTINS; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 0030761735     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Gullick, W. J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull., 47: 87-98, 1991.
2. Neal, D., Sharples, L., Smith, K., Fennelly, J., Hall, R., and Harris, A. Epidermal growth factor receptors and the prognosis of bladder cancer. Cancer (Phila.), 65: 1619-1625, 1990.
3. Mellon, J. K., Cook, S., Chambers, P., and Neal, D. E. Transforming growth factor α and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor. Br. J. Cancer, 73: 654-658, 1996.
4. Messing, E. M., Hanson, P., Ulrich, P., and Erturk, E. Epidermal growth factor interactions with normal and malignant urothelium: in vivo and in situ studies. J. Urol., 138: 1329-1335, 1987.
5. Khazaie, K., Shirrmacher, V., and Lichtner, R. B. EGF receptor in neoplasia and metastasis. Cancer Metastasis Review, 12: 255-274, 1993.
6. Chin, Y. E., Kitagawa, M., Su, W. S., You, Z., Iwamoto, Y., and Fu, X. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1. Science (Washington DC), 272: 719-722, 1996.
7. Mansbridge, J. N., Ausserer, W. A., Knapp, M. A., and Sutherland, R. M. Adaptation of EGF receptor signal transduction to three-dimensional culture conditions: changes in surface receptor expression and protein tyrosine phosphorylation. J. Cell. Physiol., 161: 374-382, 1994.
8. Kondo, S., Barna, B. P., Kondo, Y., Tanaka, Y., Casey, G., Liu, J., Morimura, T., Kaakaji, R., Peterson, J. W., Werbel, B., and Barnett, G. H. WAF1/CIP1 increases the susceptibility of p53 nonfunctional malignant glioma cells to cisplatin-induced apoptosis. Oncogene, 13: 1279-1285, 1996.
9. Sutherland, R. M. Cell and environment interaction in tumor microregions: hte multicell spheroid model. Science (Washington DC), 240: 177-184, 1988.
10. Ribiero, J. C. C., Hanley, J. R., and Russel, P. J. Studies of X-irradiated bladder cancer cell lines showing differences in p53 status: absence of a p53-dependent cell cycle checkpoint pathway. Oncogene, 13: 1269-1278, 1996.
11. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
12. Kobayashi, H., Man, S., Graham, C. H., Kapitain, S. J., Teicher, B. A., and Kerbel, R. Acquired multicellular mediated resistance to alkylating agents in cancer. Proc. Natl. Acad. Sci. USA, 90: 3294-3298, 1993.
13. Fan, Z., Lu, Y., Wu, X., DeBlasio, A., Koff, A., and Mendelsohn, J. Prolonged induction of p21 CIP1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J. Cell Biol., 131: 235-242, 1995.
14. Waldman, T., Lengauer, C., Kinzler K. W., and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (Lond.), 381: 713-716, 1996.
15. Boudreau, N., Werb, Z., and Bissell, M. J. Suppression of apoptosis by basement membrane requires three-dimensional tissue organization and withdrawal from the cell cycle. Proc. Natl. Acad. Sci. USA, 93: 3509-3513, 1996.
16. Barnes, S. Effect of genistein on in vitro and in vivo models of cancer. J. Nutr., 125: 777S-783S, 1995.
17. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
18. SAS Institute Inc., SAS/STAT User's Guide. Cary, NC: SAS Institute Inc., 1990.